Microsatellite Instability

• Microsatellite Instability (MSI) refers to changes in the length of short, repetitive DNA sequences called microsatellites.
• MSI results from a dysfunctional DNA mismatch repair (MMR) system, leading to an accumulation of mutations.
• It is a significant biomarker in several cancers, notably colorectal, endometrial, and gastric cancers.
• Detecting MSI helps predict prognosis and guides treatment decisions, particularly for immunotherapy.
• MSI testing is a crucial tool in precision oncology, identifying patients likely to benefit from specific therapies.

What is Microsatellite Instability (MSI)?

Microsatellite Instability (MSI) refers to a condition characterized by changes in the length of short, repetitive DNA sequences known as microsatellites. These sequences, typically 1-6 base pairs long, are scattered throughout the human genome. The microsatellite instability definition centers on the fact that these alterations arise due to errors during DNA replication that are not corrected by the cell’s normal DNA mismatch repair (MMR) system. When the MMR system is deficient, these replication errors accumulate, leading to either insertions or deletions in the microsatellite regions, thus making them unstable. This phenomenon is often microsatellite instability explained as a hallmark of a compromised DNA repair mechanism.

The DNA mismatch repair (MMR) system is a crucial cellular pathway responsible for identifying and correcting errors that occur during DNA replication. Genes commonly involved in MMR include MLH1, MSH2, MSH6, and PMS2. Mutations or epigenetic silencing in any of these genes can lead to a deficient MMR system, subsequently causing MSI. The presence of MSI indicates a high mutational burden within the tumor, which has significant implications for cancer development and treatment response.

Microsatellite Instability in Cancer

The presence of microsatellite instability in cancer is a well-established biomarker with profound clinical implications. It is particularly prevalent in certain types of solid tumors, most notably colorectal cancer, where it is found in about 15% of sporadic cases and nearly all cases associated with Lynch syndrome (hereditary nonpolyposis colorectal cancer). Beyond colorectal cancer, MSI is also observed in endometrial, gastric, ovarian, and small intestine cancers, among others. The accumulation of mutations due to MSI can affect genes involved in cell growth, differentiation, and apoptosis, contributing to tumor initiation and progression.

Cancers with high MSI (MSI-H) are often characterized by a large number of somatic mutations and a high density of tumor-infiltrating lymphocytes. This unique immunological profile makes MSI-H tumors particularly responsive to immune checkpoint inhibitors. For instance, studies have shown that patients with MSI-H metastatic colorectal cancer treated with PD-1 inhibitors like pembrolizumab have significantly better response rates compared to those with microsatellite stable (MSS) tumors. According to the National Cancer Institute, MSI-H status is recognized as a pan-cancer biomarker for predicting response to immunotherapy.

Detecting MSI and Clinical Significance

Detecting MSI is a routine part of cancer diagnostics, primarily performed using molecular techniques. The two main methods are polymerase chain reaction (PCR) and immunohistochemistry (IHC). PCR-based assays analyze the length of specific microsatellite markers in tumor DNA compared to normal tissue DNA. IHC, on the other hand, detects the absence of specific MMR proteins (MLH1, MSH2, MSH6, PMS2) in tumor cells, which indirectly indicates an MMR deficiency and thus MSI.

The clinical significance of MSI testing is multifaceted:

• Prognosis: In some cancers, like stage II colorectal cancer, MSI-H status is associated with a better prognosis but may indicate a lack of benefit from adjuvant 5-fluorouracil chemotherapy.
• Treatment Guidance: MSI status is a crucial predictive biomarker for immunotherapy. Patients with MSI-H tumors across various cancer types are more likely to respond to immune checkpoint blockade therapies, such as PD-1/PD-L1 inhibitors. This has revolutionized treatment strategies for these patients, offering new therapeutic avenues.
• Lynch Syndrome Screening: MSI testing, often combined with IHC, is a primary screening tool for identifying individuals who may have Lynch syndrome, a hereditary condition that significantly increases the risk of several cancers. Further genetic testing can then confirm the diagnosis.

The integration of MSI testing into clinical practice has significantly advanced precision oncology, allowing for more tailored and effective treatment approaches for patients with MSI-positive tumors.